120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
血清Midkine作为儿童哮喘疾病严重程度和重塑相关介质的潜在生物标志物
Authors Xu Y, Zhao L, Mi Y, Ge Y, Guo Y
Received 17 October 2025
Accepted for publication 12 January 2026
Published 20 January 2026 Volume 2026:19 570351
DOI https://doi.org/10.2147/JAA.S570351
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Luis Garcia-Marcos
Yongtian Xu,* Lixia Zhao,* Yingying Mi, Yi Ge, Yanfang Guo
Department of Pediatrics, Shanghai University of Medicine and Health Science Affiliated Gongli Hospital, Shanghai, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yanfang Guo, Department of Pediatrics, Shanghai University of Medicine and Health Science Affiliated Gongli Hospital, No. 219 Miaopu Road, Pudong New District, Shanghai, 200135, People’s Republic of China, Tel +86-15221709828, Email 15221709828@163.com
Introduction: Asthma is a heterogeneous inflammatory airway disease in children, for which reliable circulating biomarkers reflecting disease severity and remodeling-associated inflammation remain limited. Midkine, a heparin-binding growth factor involved in inflammatory and fibrotic processes, has emerged as a potential biomarker; however, its clinical relevance in pediatric asthma remains unclear. This study aimed to investigate the association between serum midkine levels and disease severity in children with asthma.
Methods: We enrolled 109 children with asthma (classified into mild, moderate, and severe groups) and 110 healthy controls. Children with asthma were classified into mild, moderate, and severe groups according to the Global Initiative for Asthma (GINA) criteria, and serum midkine levels were measured by ELISA, along with clinical and lung function assessments.
Results: Serum midkine levels were significantly higher in children with asthma than in healthy controls and increased progressively with disease severity. Receiver operating characteristic analysis demonstrated good diagnostic performance of serum midkine for asthma (AUC = 0.949), with a sensitivity of 87.2% and specificity of 94.5% at a cutoff value of 948 pg/mL. Additionally, serum midkine levels were negatively correlated with lung function parameters (FEV1, FEV1/FVC, and PEF) and positively correlated with eosinophilia, total immunoglobulin E (IgE), fractional exhaled nitric oxide (FeNO), pro-inflammatory cytokines, and remodeling-related mediators.
Conclusion: These findings highlight midkine as a promising biomarker and potential therapeutic target for asthma.
Keywords: asthma, midkine, inflammation, lung function, airway remodeling, biomarker
Department of Pediatrics, Shanghai University of Medicine and Health Science Affiliated Gongli Hospital, Shanghai, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yanfang Guo, Department of Pediatrics, Shanghai University of Medicine and Health Science Affiliated Gongli Hospital, No. 219 Miaopu Road, Pudong New District, Shanghai, 200135, People’s Republic of China, Tel +86-15221709828, Email 15221709828@163.com
Introduction: Asthma is a heterogeneous inflammatory airway disease in children, for which reliable circulating biomarkers reflecting disease severity and remodeling-associated inflammation remain limited. Midkine, a heparin-binding growth factor involved in inflammatory and fibrotic processes, has emerged as a potential biomarker; however, its clinical relevance in pediatric asthma remains unclear. This study aimed to investigate the association between serum midkine levels and disease severity in children with asthma.
Methods: We enrolled 109 children with asthma (classified into mild, moderate, and severe groups) and 110 healthy controls. Children with asthma were classified into mild, moderate, and severe groups according to the Global Initiative for Asthma (GINA) criteria, and serum midkine levels were measured by ELISA, along with clinical and lung function assessments.
Results: Serum midkine levels were significantly higher in children with asthma than in healthy controls and increased progressively with disease severity. Receiver operating characteristic analysis demonstrated good diagnostic performance of serum midkine for asthma (AUC = 0.949), with a sensitivity of 87.2% and specificity of 94.5% at a cutoff value of 948 pg/mL. Additionally, serum midkine levels were negatively correlated with lung function parameters (FEV1, FEV1/FVC, and PEF) and positively correlated with eosinophilia, total immunoglobulin E (IgE), fractional exhaled nitric oxide (FeNO), pro-inflammatory cytokines, and remodeling-related mediators.
Conclusion: These findings highlight midkine as a promising biomarker and potential therapeutic target for asthma.
Keywords: asthma, midkine, inflammation, lung function, airway remodeling, biomarker